Neoadjuvant Docetaxel and Capecitabine in Patients With High Risk Prostate Cancer

Journal of Urology

Volumn 179, Issue 3, 2008, Pages 911-916

  Friedman, Judah ^a   Dunn, Rodney L ^a   Wood, David ^a   Vaishampayan, Ulka ^b   Wu, Angela ^a   Bradley, Deborah ^a   Montie, James ^a   Sarkar, Fazlul H ^b   Shah, Rajal B ^a   Hussain, Maha ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

drug therapy; prostatic neoplasms

Indexed keywords

CAPECITABINE; DEXAMETHASONE; DOCETAXEL; MARKER; PROSTATE SPECIFIC ANTIGEN; SERUM APOPTOSIS MARKER; SURVIVIN; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; CANCER STAGING; CHEMOTHERAPY INDUCED APOPTOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATIONAL STUDY; DIARRHEA; DIGITAL RECTAL EXAMINATION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; GASTROINTESTINAL SYMPTOM; GLEASON SCORE; HAND FOOT SYNDROME; HIGH RISK PATIENT; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFREQUENT DIARRHEA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; PHYSICAL EXAMINATION; PREMEDICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SIDE EFFECT; TASTE DISORDER; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 39149130326     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.10.064     Document Type: Article

References (19)

1. Partin A.W., Yoo J., Carter H.B., Pearson J.D., Chan D.W., Epstein J.L., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110
2. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781
3. Bola M., Gonzalez D., Warde P., Dubois J.B., Mirimanoff R.O., Storme G., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295
4. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502
5. Petrylak D.P., Tangen C.M., Hussain M.H., Laura P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513
6. Hussain M., Smith D.C., El-Rayes B.F., Du W., Vaishampayan U., Fontana J., et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 61 (2003) 774
7. Dreicer R., Magi-Galluzzi C., Zhou M., Rothaermel J., Reuther A., Ulchaker J., et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63 (2004) 1138
8. Febbo P.G., Richie J.P., George D.J., Manola J., Shankar S., Barnes A.S., et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11 (2005) 5233
9. Takebayashi Y., Yamada K., Miyadera K., Sumizawa T., Furukawa T., Kinoshita F., et al. The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A (1996) 1227
10. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., and Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58 (1998) 685
11. Sawada N., Ishikawa T., Fukase Y., Nishida M., Yoshikubo T., and Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4 (1998) 1013
12. O'Shaughnessy J., Miles D., Vukelja S., Moiseyenko V., Ayoub J.P., Cervantes G., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III results. J Clin Oncol 20 (2002) 2812
13. Li Y., Hussain M., Sarkar S.H., Eliason J., Li R., and Sarkar F.H. Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells. BMC Cancer 5 (2005) 7
14. Kishi H., Igawa M., Kikuno N., Yoshino T., Urakami S., and Shiina H. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 171 (2004) 1855
15. Nadella P., Shapiro C., Otterson G., Hauger M., Erdal S., Kraut E., et al. A pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 20 (2002) 2616
16. Petraki C.D., and Sfikas C.P. Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol 22 (2007) 107
17. Biven K., Erdal H., Hagg M., Ueno T., Zhou R., Rowley B., et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 8 (2003) 263
18. Gleave M.E., Goldenberg S.L., Jones E.C., Bruchovsky N., and Sullivan L.D. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155 (1996) 213
19. Bear H.D., Anderson S., Smith R.E., Geyer C.E., Mamounas E.P., Fisher B., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24 (2006) 2019